Literature DB >> 29129675

Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease.

Nikolaos Papagiannakis1, Christos Koros2, Maria Stamelou2, Athina-Maria Simitsi2, Matina Maniati3, Roubina Antonelou2, Dimitra Papadimitriou4, Georgia Dermentzaki3, Marina Moraitou5, Helen Michelakakis5, Leonidas Stefanis6.   

Abstract

BACKGROUND: Variations of α-synuclein levels or species have been reported in Parkinson's Disease (PD). There has been little systematic examination of erythrocytes, a rich source of α-synuclein.
METHODS: Erythrocyte membranes were obtained from PD patients (mutation carriers in the α-synuclein gene (A53T-PD) and glucocerebrosidase gene (GBA-PD) (n=18 each), and patients without known mutations (GU-PD, n=56)), and age-/sex-matched controls (n=56). Levels of monomeric and dimeric α-synuclein were assessed using Western immunoblotting.
RESULTS: A statistically significant increase of α-synuclein dimer and dimer to monomer ratio was found in GBA-PD and GU-PD. In contrast, dimer levels of A53T-PD were not different from controls. No difference was found in α-synuclein monomer levels.
CONCLUSIONS: The increased α-synuclein dimer in GBA-PD and GU-PD is suggestive of an apparent systemic dysfunction causing the dimerization, and potentially oligomerization, of α-synuclein. These results may have implications for PD pathogenesis and biomarker development.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Alpha-synuclein dimers; Alpha-synuclein oligomers; Erythrocytes; Glucocerebrosidase; Red blood cells

Mesh:

Substances:

Year:  2017        PMID: 29129675     DOI: 10.1016/j.neulet.2017.11.012

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

2.  α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease.

Authors:  Zongran Liu; Robin Barry Chan; Zhijian Cai; Xiaodan Liu; Yufeng Wu; Zhenwei Yu; Tao Feng; Ying Yang; Jing Zhang
Journal:  J Neuroinflammation       Date:  2022-02-22       Impact factor: 8.322

Review 3.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

4.  Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.

Authors:  Colleen S Limegrover; Raymond Yurko; Nicholas J Izzo; Kelsie M LaBarbera; Courtney Rehak; Gary Look; Gilbert Rishton; Hank Safferstein; Susan M Catalano
Journal:  J Neurosci Res       Date:  2021-01-22       Impact factor: 4.164

5.  α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity.

Authors:  Simona Daniele; Daniela Frosini; Deborah Pietrobono; Lucia Petrozzi; Annalisa Lo Gerfo; Filippo Baldacci; Jonathan Fusi; Chiara Giacomelli; Gabriele Siciliano; Maria Letizia Trincavelli; Ferdinando Franzoni; Roberto Ceravolo; Claudia Martini; Ubaldo Bonuccelli
Journal:  Front Mol Neurosci       Date:  2018-02-22       Impact factor: 5.639

6.  Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis.

Authors:  Lifu Sheng; Tessandra Stewart; Dishun Yang; Eric Thorland; David Soltys; Patrick Aro; Tarek Khrisat; Zhiying Xie; Na Li; Zongran Liu; Chen Tian; Matthew Bercow; Junichi Matsumoto; Cyrus P Zabetian; Elaine Peskind; Joseph F Quinn; Min Shi; Jing Zhang
Journal:  Acta Neuropathol Commun       Date:  2020-07-08       Impact factor: 7.801

7.  Elevated circulating magnesium levels in patients with Parkinson's disease: a meta-analysis.

Authors:  Xin Jin; Ming-Yan Liu; Dong-Fang Zhang; Hua Gao; Min-Jie Wei
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-19       Impact factor: 2.570

8.  Erythrocytic α-Synuclein as a potential biomarker for Parkinson's disease.

Authors:  Chen Tian; Genliang Liu; Liyan Gao; David Soltys; Catherine Pan; Tessandra Stewart; Min Shi; Zhiying Xie; Na Liu; Tao Feng; Jing Zhang
Journal:  Transl Neurodegener       Date:  2019-05-15       Impact factor: 8.014

Review 9.  Impact of gene mutation in the development of Parkinson's disease.

Authors:  Suganya Selvaraj; Shanmughavel Piramanayagam
Journal:  Genes Dis       Date:  2019-02-27

Review 10.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.